<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654587</url>
  </required_header>
  <id_info>
    <org_study_id>OSE2101C301</org_study_id>
    <secondary_id>2015-003183-36</secondary_id>
    <nct_id>NCT02654587</nct_id>
  </id_info>
  <brief_title>Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor</brief_title>
  <acronym>ATALANTE 1</acronym>
  <official_title>A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small-Cell Lung Cancer With Progressive Disease After Last Treatment With Immune Checkpoint Inhibitors (ICI). (OSE2101C301)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OSE Immunotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OSE Immunotherapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine if the Investigational Medicinal Product Tedopi
      (OSE2101) is more effective than standard treatment in treating patients with stage IIIB
      NSCLC unsuitable for radiotherapy or metastatic NSCLC in second- or third-line treatment
      after failure of immune checkpoint-inhibitor regimens.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Step 1 primary objective: Overall Survival rate (approx. 100 patients) / Step 2 primary objective: Overall Survival (approx. 363 patients in total, number to be reassessed based on the step 1 results)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival time (OS)</measure>
    <time_frame>Approx. 24 months</time_frame>
    <description>In Step 1: OS rate at 12 months in experimental Arm A (OSE2101) in 84 evaluable patients exposed to OSE2101
In Step 2: comparison of OS between experimental Arm A (OSE2101) and control Arm B (docetaxel or pemetrexed) when 278 events observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-C30 (EORTC QLQ questionnaire): &quot;Global health status/QoL&quot; score based on questions 29</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-LC13 (lung cancer module from EORTC QLQ questionnaire): time to 1st ≥ 10-point deterioration in (question 40), dyspnea (questions 33, 34, 35) or cough (question 31)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) (in Step 1 only)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR at 12 months (in Step 1 only)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR) (in Step 1 only)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability profile compared to the control group</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Objective Response Rate (ORR) (In Step 2 only)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease Control Rate (DCR) at 12 months (In Step 2 only)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Response (DR) (In Step 2 only)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to deterioration (TTD)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to next lung cancer therapy</measure>
    <time_frame>Approx. 24 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">363</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>OSE2101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSE2101 will be administered as a 1 mL-subcutaneous injection on Day 1 every three weeks for six cycles, then every eight weeks for the remainder of year one and finally every twelve weeks beyond year one until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal. Should pseudo progression or delayed response to treatment suspected in arm A, investigator may continue treatment beyond the time of RECIST-defined progression, if the patient is perceived to be experiencing clinical benefit. OSE2101 dose will be 5 mg of peptide (0.5 mg for each peptide).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel or Pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving docetaxel: Docetaxel 75 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of a 21-day cycle.
Patients receiving pemetrexed: Pemetrexed, 500 mg/m2, will be administered by intravenous infusion over 10 minutes on Day 1 of a 21-day cycle.
Docetaxel and pemetrexed will be continued until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSE2101</intervention_name>
    <arm_group_label>OSE2101</arm_group_label>
    <other_name>Tedopi</other_name>
    <other_name>EP-2101</other_name>
    <other_name>EP2101</other_name>
    <other_name>IDM-2101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Docetaxel or Pemetrexed</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Docetaxel or Pemetrexed</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent document indicating that the patient has been
             informed of all the pertinent aspects of the trial prior to enrollment.

          2. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures.

          3. Female or male, 18 years of age or older.

          4. Histologically or cytologically proven diagnosis of NSCLC that is locally advanced
             (stage III) unsuitable for radiotherapy or metastatic (stage IV) according to the 8th
             edition of tumor, node, metastasis (TNM) in Lung Cancer published by the International
             Union Against Cancer and the American Joint Committee on Cancer.

          5. Subjects with disease recurrence or progression After therapy with an immune
             checkpoint inhibitor and platinum-based chemotherapy i) either 1st line chemotherapy
             followed by 2nd line checkpoint inhibitor, or ii) 1st line combination of checkpoint
             inhibitor and chemotherapy Patients with progression during or within 12 months after
             the end of ICI as sequential or concomitant platinum-based chemotherapy ± radiation
             for locally advanced disease (stage III) are eligible

          6. Subjects with measurable or non-measurable lesions.

          7. Subjects must express HLA-A2 phenotype as assessed serologically.

          8. Subjects must be considered suitable for chemotherapy with either single-agent
             pemetrexed or docetaxel.

          9. Subjects with brain metastases are eligible if treated (whole brain radiotherapy,
             stereotaxic radiotherapy, surgery) at least 3 weeks prior to initiation of study
             treatment and have no symptoms related to brain metastases for at least 2 weeks before
             initiation of study treatment and are not taking any forbidden medications.

         10. Any prior chemotherapy, immunotherapy, hormonal therapy, radiation therapy or
             surgeries must have been completed at least 3 weeks prior to initiation of study
             treatment.

         11. Any toxicity from prior therapy must have recovered to ≤ Grade 1 (except alopecia).

         12. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

         13. Adequate organ function as defined by all the following criteria:

               -  Albuminemia &gt; 25g/L

               -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 1.5 x
                  upper limit of normal (ULN) with alkaline phosphatase ≤ 2.5 x ULN, or AST and ALT
                  ≤ 5 x ULN if liver function abnormalities are due to liver metastases

               -  Total serum bilirubin ≤ 1.5 x ULN

               -  Absolute neutrophil count (ANC) ≥ 1500/L

               -  Platelets ≥ 100000/L

               -  Hemoglobin ≥ 9.0 g/dL (in the absence of transfusion within 2 weeks before
                  randomization)

               -  Creatinine clearance (based on modified Cockcroft-Gault formula) ≥ 45 ml/min.

        Exclusion Criteria:

          1. Small-cell lung cancer/mixed NSCLC with small cell component or other neuroendocrine
             lung cancers (typical and atypical carcinoids, large-cell neuroendocrine carcinomas).

          2. Patients with squamous cell carcinoma histology, and who had docetaxel as part of his
             prior chemotherapy.

          3. Current or previous treatment with investigational therapy in another therapeutic
             clinical trial (interrupted less than 4 weeks before study treatment initiation).

          4. Patients whose tumor harbors EGFR gene mutation that sensitizes tumors to
             Tyrosine-Kinase Inhibitor (TKI) (EGFR exon 18-21) or Anaplastic Lymphoma Kinase (ALK)
             rearrangement.

          5. Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy that would be
             scheduled to continue concomitantly to the study).

          6. Spinal cord compression (unless treated with the patient attaining good pain control
             and stable or recovered neurologic function), carcinomatous meningitis, or
             leptomeningeal disease

          7. Patients with squamous cell histology or non-squamous cell histology previously
             treated by pemetrexed with a contraindication for docetaxel with grade ≥ 2 neuropathy
             or hypersensitivity reaction to medications formulated with polysorbate 80 (Tween 80)
             as they could be randomly assigned to Arm B.

          8. Patients with a condition requiring systemic treatment with either corticosteroids or
             other immunosuppressive medications.

          9. Treatment with corticosteroids in the last 3-week period before inclusion, except for
             topical, ocular, intra-articular, intranasal, and inhaled corticosteroids with minimal
             systemic absorption (e.g. with a dose ≤ 500 microgram beclomethasone equivalent for
             inhaled steroids), or steroid doses ≤ 10 mg daily prednisone equivalent which are
             permitted.

         10. A recognized immunodeficiency disease including human immunodeficiency virus (HIV)
             infection (and other cellular immunodeficiencies, hypogammaglobulinemia or
             dysgammaglobulinemia; subjects who have hereditary, congenital or acquired
             immunodeficiencies).

         11. Patients with auto-immune disease, with the exception of type I diabetes or treated
             hypothyroidism.

         12. Patients with interstitial lung disease.

         13. Patients with active B or C hepatitis.

         14. Other malignancy: patients will not be eligible if they have evidence of other active
             invasive cancer(s) (other than NSCLC) within 5 years prior to screening (except
             appropriately treated non-melanoma skin cancer or localized cervical cancer, or other
             local tumors considered cured (e.g.localized and presumed cured prostate cancer).

         15. Other severe acute or chronic medical or psychiatric conditions, or laboratory
             abnormalities that would impart, in the judgment of the investigator and/or sponsor,
             excess risk associated with study participation or study drug administration, and
             which would, therefore, make the patient inappropriate for entry into this study.

         16. Female patients must be surgically sterile or be postmenopausal, or must agree to use
             effective contraception during the period of the trial and for at least 90 days after
             completion of treatment.

         17. Male patients sexually active with a woman of childbearing potential must be
             surgically sterile or must agree to use effective contraception during the period of
             the trial and for at least 90 days after completion of treatment. The decision of
             effective contraception will be based on the judgment of the principal investigator.

         18. Breastfeeding women.

         19. Women with a positive pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bérangère Vasseur, MD</last_name>
    <email>berangere.vasseur@ose-immuno.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>East Valley Hematology and Oncology medical Group</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Bardens</last_name>
      <phone>818-748-4793</phone>
      <email>jenny.bardens@providence.org</email>
    </contact>
    <investigator>
      <last_name>Ravi Shankar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannette Crawford</last_name>
      <phone>202-687-0893</phone>
      <email>crawfojg@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Giaconne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennington Cancer Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pontchartrain Cancer Center</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Faucheaux</last_name>
      <email>jfaucheaux@pcclouisiana.com</email>
    </contact>
    <investigator>
      <last_name>David Oubre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Touro Infirmary</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center (NMMC)-Hematology and Oncology Clinic</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Meridian Health</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne Valasa</last_name>
      <phone>732-450-2721</phone>
      <email>rvalasa@meridianhealth.com</email>
    </contact>
    <investigator>
      <last_name>Jatin K Desani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Dunn</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>209</phone_ext>
      <email>bdunn@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Yarbrough</last_name>
      <phone>405-271-8777</phone>
      <email>melissa-yarbrough@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammad Razaq, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert W. Franz Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Tripp</last_name>
      <phone>503-215-2614</phone>
      <email>canrsrchstudies@providence.org</email>
    </contact>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gesinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peg Reed</last_name>
      <phone>570-214-9603</phone>
      <email>mmreed@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Rajiv Panikkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Warner</last_name>
      <phone>717-334-4033</phone>
      <phone_ext>141</phone_ext>
      <email>vwarner@gettysburgoncology.com</email>
    </contact>
    <investigator>
      <last_name>Tina Khair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Millenium Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Waldron</last_name>
      <phone>877-870-2640</phone>
      <email>JWaldron@wmrad.com</email>
    </contact>
    <investigator>
      <last_name>Anirudha Dasgupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava, Onkologické oddelení</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Krajská nemocnice Liberec</name>
      <address>
        <city>Liberec</city>
        <zip>46063</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut onkologie a rehablilitace na Plesi</name>
      <address>
        <city>Nová Ves Pod Pleší</city>
        <zip>26204</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinika tuberkulózy a respiracních nemocí, FNO</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pardubická krajská nemocnice</name>
      <address>
        <city>Pardubice</city>
        <zip>53203</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Všeobecná Fakultní nemocnice</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Masarykova nemocnice v Usti nad Labem</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut Saint Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Bois</last_name>
      <phone>0033 (0)4 9027 6110</phone>
      <email>v.bois@isc84.org</email>
    </contact>
    <investigator>
      <last_name>Werner Hilgers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadhila Messani</last_name>
      <email>fadhila.messani@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Boris Duchemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie Ducasse</last_name>
      <phone>+33 5 56 33 32 22</phone>
      <email>e.ducasse@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Cousin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHGU Morvan - Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amélie Crie</last_name>
      <email>amelie.crie@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Robinet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaële Guelminger</last_name>
      <phone>+33 4 72 35 70 74</phone>
      <email>raphaele.guelminger@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Marylise Ginoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Vallée</last_name>
      <phone>0033 2 41 49 69 91</phone>
      <email>laura.vallee@ch-cholet.fr</email>
    </contact>
    <contact_backup>
      <last_name>Phillippe Masson, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane JOLLY, MD</last_name>
      <phone>+33 (0)1 57 02 24 42</phone>
      <email>stephane.jolly@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Christos Chouaid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de lutte contre le cancer Georges-François Leclerc (CGFL Dijon)</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile GLOMMEAU</last_name>
      <phone>0033 4 76 76 75 75</phone>
      <phone_ext>6 44 67</phone_ext>
      <email>cglommeau@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Denis Moro-Sibilot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Sacier</last_name>
      <phone>+33 2 43 29 79 08</phone>
      <email>vsacier_sorecoh@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice Denis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anaig Le Cam</last_name>
      <phone>+33 2 44 71 02 65</phone>
      <email>alecam@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Molinier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Albert Calmette</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Grammont</last_name>
      <email>marie.grammont@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Alexis Cortot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paoli-Calmettes Institute</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Ize</last_name>
      <email>izef@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Madroszyk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lily Rasoamanana</last_name>
      <email>l-rasoamanana@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Benoît Roch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie BIRR</last_name>
      <phone>+33 (0)3 89 64 61 23</phone>
      <email>birrv@ghrmsa.fr</email>
    </contact>
    <investigator>
      <last_name>Didier Debieuvre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>soraya Merbah</last_name>
      <phone>01 42 49 49 49</phone>
      <phone_ext>2 67 77</phone_ext>
      <email>soraya.merbah@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Ludovic Doucet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européens Georges Pompidou (HEGP)</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat - Claude-Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie Prigent</last_name>
      <phone>+33 2 99 28 97 95</phone>
      <email>melanie.prigent@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Romain Corre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Bégin</name>
      <address>
        <city>Saint Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc FERRAND</last_name>
      <phone>0033 4 76 76 51 43</phone>
      <email>LFerrand1@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>François-Régis Ferrand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss (CLCC)</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manon VOEGELIN</last_name>
      <phone>+33 (0)3 88 25 85 41</phone>
      <email>MVoegelin@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Roland Schott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koukeb Malki-Rouguieg</last_name>
      <phone>+33 3 69 55 16 75</phone>
      <email>koukeb.malki-rouguieg@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Quoix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey - CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie Rayez</last_name>
      <phone>+33 2 47 47 47 47</phone>
      <email>m.rayez@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Pichon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Troyes</name>
      <address>
        <city>Troyes</city>
        <zip>10003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yana Chaban</last_name>
      <email>nana.chaban@ch-troyes.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand Delclaux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy (IGR)</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UniversitätsKlinikum Heidelberg</name>
      <address>
        <city>Bergheim</city>
        <zip>68750</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Mehrheit - Kliniken der Stadt Köln - Lungenklinik</name>
      <address>
        <city>Cologne</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gudrun Klauke</last_name>
      <phone>+49 221 8907 13962</phone>
      <email>klaukeg@kliniken-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Walburga Engel-Riedel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera Thorax und Gefäßchirurgie Angiologie</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin II Hospital Martha-Maria Halle-Dölau gGmbH</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Gebauer</last_name>
      <phone>+49 345 559 1434</phone>
      <email>Studiensekretariat.Schuette@nicsys.de</email>
    </contact>
    <investigator>
      <last_name>Wolfang Schutte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Cancer Research Center (DKFZ)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Lungenkrebszentrum an der Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Bogenhausen Städtisches Klinikum München GmbH</name>
      <address>
        <city>Munich</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pius-Hospital Oldenburg Klinik für Hämatologie und Onkologie</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelika Nintemann</last_name>
      <phone>0049 441 229 1691</phone>
      <email>Angelika.Nintemann@Pius-Hospital.de</email>
    </contact>
    <investigator>
      <last_name>Frank Griesinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen Medizinische Klinik II</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin II Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Wuppertal Medizinische Klinik 1 für Hämatologie Onkologie Nephrologie</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegugyi Kozpont II szamu telephely</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Országos Korányi TBC és Pulmonológiai Intézet IV Tüdőbelosztály</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Országos Korányi TBC és Pulmonológiai Intézet XI Tüdőbelosztály</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Országos Korányi TBC és Pulmonológiai Intézet XIV Tüdőbelosztály</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Altalanos Orvostudományi Kar Pulmonologiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Csongrad Megyei Mellkasi Betegsegek Szakkorháza I Tüdőosztály</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Miskolci Sugárterápiás és Klinikai Onkológiai Intézet</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Kft.</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Matrai Gyogyintézet</name>
      <address>
        <city>Mátraháza</city>
        <zip>3233</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Pulmonology and Thoracic Oncology</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilona Hanukov</last_name>
      <phone>+972 503280496</phone>
      <email>IlonaH@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Nir Peled, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marianna Wollner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Campus Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <zip>9087200</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilad Arfa</last_name>
      <phone>00972 (0)50 685 7160</phone>
      <email>gilada@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Hovav Nechushtan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kefar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mor Avi</last_name>
      <phone>+972 (9) 7471946</phone>
      <email>aviva.mor@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Goetfried Maya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin (Belinson) Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shani Gridinger</last_name>
      <phone>+972-3-9378089</phone>
      <email>shanigr@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Alona Zer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziv MC, HaRambam Rd.</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gamal Zidan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center (Ichilov Hospital)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagit Damchiner-Pearl</last_name>
      <phone>00972 (0)3 694 7568</phone>
      <email>hagitdp@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ofer Merimsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Oncologico Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petrillo Patrizia</last_name>
      <phone>+39 080-5555442</phone>
      <email>galetta@oncologico.bari.it</email>
    </contact>
    <investigator>
      <last_name>Domenico Galetta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Oncologia dell'Ospedale Vito Fazzi di Lecce, Piazza Muratore</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annamaria Mauro, MD</last_name>
      <phone>0039 0832661962</phone>
      <email>mauroannamaria@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giampero Romano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia medica</name>
      <address>
        <city>Legnano</city>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Insolda</last_name>
      <phone>0039 0442622801</phone>
      <email>oncologia.medica.leg@aulss9.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Bonetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda USL 2 Lucca - Dipartimento Oncologico</name>
      <address>
        <city>Lucca</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Delle Mura</last_name>
      <phone>+39 0583 449545</phone>
      <email>sperimentazione.oncologia@usl2.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Editta Baldini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T)</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgia Ravaglia</last_name>
      <phone>0039 0543 739268</phone>
      <email>giorgia.ravaglia@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Angelo Delmonte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Pneumologia a indirizzo oncologico, Presidio Ospedaliero Monaldi - Azienda Ospedaliera dei Colli - Via Leonardo Bianchi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto, IRCCS</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laura Bonanno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Perugia - Oncologia medica</name>
      <address>
        <city>Perugia</city>
        <zip>06126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincenzo Minotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria pisana Pneumologia 2</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>U.O Oncologia ed Ematologia, Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Spreafico</last_name>
      <phone>0039 0544 285206</phone>
      <email>michaela.spreafico@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Federico Cappuzzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Ospedale Infermi</name>
      <address>
        <city>Rimini</city>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuliana Drudi</last_name>
      <phone>0039 0541 705413</phone>
      <email>datamanager.oncologiarimini@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Davide Tassinari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC di Oncologia Medica, Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Nuovo Regina Margherita</name>
      <address>
        <city>Roma</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Santa Maria alle Scotte</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Ibba</last_name>
      <phone>+39 5 77 58 63 26</phone>
      <email>ibbaelisa24@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Michele Maio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Maggiore</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospicjum im. Ks. Eugeniusza Dutkiewicza SAC</name>
      <address>
        <city>Gdansk</city>
        <zip>80-208</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinika Onkologii i Radioterapii , Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Przychodnia Lekarska &quot;KOMED&quot;</name>
      <address>
        <city>Konin</city>
        <zip>62-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boguslawa Karaszewska, MD</last_name>
      <phone>+48 664 134 814</phone>
      <email>karasiowa@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Boguslawa Karaszewska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Oddział Onkologii z Pododdziałem Chemioterapii Nowotworów Płuc Samodzielny Publiczny Zespół Gruźlicy i Chorób Płuc w Olsztynie&quot;</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mazowieckie Centrum Leczenia chorób Płuc i Gruźlicy</name>
      <address>
        <city>Otwock</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kowalska</last_name>
      <phone>+48 22 344 63 01</phone>
      <email>koordynator.otwock1@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Aleksandra Szczęsna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego Im. Karola Marcinkowskiego Oddział Chemioterapii</name>
      <address>
        <city>Poznań</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Zespolony , Oddział Chemioterapii Nowotworów</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Sawrycki, MD</last_name>
      <phone>48 56 61 01 390</phone>
      <email>piotrsaw@am.torun.pl</email>
    </contact>
    <investigator>
      <last_name>Piotr Sawrycki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Szpital Im. Prof. Alfreda Sokołowskiego</name>
      <address>
        <city>Zdunowo</city>
        <zip>70-891</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laia Laverna</last_name>
      <email>LLavernia@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Margarita Majem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Ovalle</last_name>
      <phone>0034935460143</phone>
      <email>eovalle@oncorosell.com</email>
    </contact>
    <investigator>
      <last_name>Santiago Viteri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergi Recasens</last_name>
      <phone>+34 934894375</phone>
      <email>srecasens@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Enriqueta Felip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Riera</last_name>
      <phone>+34 934978729</phone>
      <email>priera@igtp.cat</email>
    </contact>
    <investigator>
      <last_name>Teresa Moran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Complejo Hospitalario Universitario A Coruna (CHUAC)&quot;</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosario GARCÍA CAMPELO, MD</last_name>
      <phone>+34 981 176 003</phone>
      <email>maria.rosario.garcia.campelo@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Rosario García Campelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Hospital Universitario Fundacion Jimenez Diaz&quot;</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manuel Domine Gómez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Gómez</last_name>
      <phone>0034914692313</phone>
      <email>abecia@h12o.es</email>
    </contact>
    <investigator>
      <last_name>Santiago Ponce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz Servicio de Oncología Médica</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel del Amo</last_name>
      <phone>0034917277516</phone>
      <email>raquel.amo.olivares@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Javier de Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda Servicio de Oncología Médica Consultas externas, 2ª planta</name>
      <address>
        <city>Madrid</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano Provencio, MD</last_name>
      <phone>+34 91 191 7148</phone>
      <email>mprovencio@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mariano Provencio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataro</name>
      <address>
        <city>Mataró</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Nuñez</last_name>
      <phone>+34 93 741 77 00</phone>
      <phone_ext>2401</phone_ext>
      <email>oncologia@csdm.cat</email>
    </contact>
    <investigator>
      <last_name>Ainhoa Hernández González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Rojas</last_name>
      <phone>+34 951291165</phone>
      <email>ensayosch@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Cobo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Hospital Universitario Miguel Servet&quot;</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ÁNGEL FERNANDO Artal Cortés, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Medway Maritime Hospital</name>
      <address>
        <city>Gillingham</city>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Guys' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institue London</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Charring Cross Hospital, Imperial College NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Chrisitie</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Milton Keynes Hospital</name>
      <address>
        <city>Milton Keynes</city>
        <zip>MK6 5LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, Ganesa P, Nemunaitis J, Ishioka G, Pappen B, Nemunaitis M, Morse M, Mills B, Maples PB, Sherman J, Nemunaitis JJ. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25. doi: 10.1200/JCO.2008.16.6462.</citation>
    <PMID>18802154</PMID>
  </reference>
  <reference>
    <citation>Beebe M, Qin M, Moi M, Wu S, Heiati H, Walker L, Newman M, Fikes J, Ishioka GY. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy. Hum Vaccin. 2008 May-Jun;4(3):210-8. Epub 2010 May 11.</citation>
    <PMID>18382135</PMID>
  </reference>
  <reference>
    <citation>Nemunaitis J, Cunningham, C ,Bender, J, Ishioka, G, Maples, P, Pappen, B, Stephenson, J, Morse, M, Mills, B, Greco, A, McCune, D, Steis, R, Nugent, F, Khong, HT, Richards, D. Phase II trial of a 10-epitope CTL vaccine, IDM-2101, in metastatic NSCLC patients: Induction of immune responses and clinical efficacy. International Society for Biological Therapy of Cancer 2007, p 891-2.</citation>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small-Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cancer vaccine</keyword>
  <keyword>Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

